S&P 500   3,841.94
DOW   31,496.30
QQQ   308.68
S&P 500   3,841.94
DOW   31,496.30
QQQ   308.68
S&P 500   3,841.94
DOW   31,496.30
QQQ   308.68
S&P 500   3,841.94
DOW   31,496.30
QQQ   308.68
Log in

ADMA Biologics Stock Forecast, Price & News

-0.14 (-6.28 %)
(As of 03/5/2021 12:00 AM ET)
Today's Range
Now: $2.09
50-Day Range
MA: $2.46
52-Week Range
Now: $2.09
Volume3.97 million shs
Average Volume4.04 million shs
Market Capitalization$197.61 million
P/E RatioN/A
Dividend YieldN/A
ADMA Biologics, Inc., a biopharmaceutical and specialty immunoglobulin company, develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States. It offers BIVIGAM, an intravenous immune globulin product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB, which is indicated for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. It also develops a pipeline of plasma-derived therapeutics, including products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, the company operates source plasma collection facilities. The company distributes its products through independent distributors, sales agents, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was founded in 2004 and is headquartered in Ramsey, New Jersey.
ADMA Biologics logo


ADMA Biologics Inc
January 21, 2021 |  reuters.com
Is ADMA A Good Stock To Buy According To Hedge Funds?
December 19, 2020 |  finance.yahoo.com
See More Headlines

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Current SymbolNASDAQ:ADMA
Year FoundedN/A



Sales & Book Value

Annual Sales$29.35 million
Book Value$0.44 per share


Net Income$-48,280,000.00
Net Margins-166.01%


Market Cap$197.61 million
Next Earnings Date3/11/2021 (Estimated)


Overall MarketRank

1.59 out of 5 stars

Medical Sector

375th out of 1,972 stocks

Biological Products, Except Diagnostic Industry

50th out of 177 stocks

Analyst Opinion: 3.5Community Rank: 3.0Dividend Strength: 0.0Insider Behavior: 0.8Valuation: 0.6 5 -4 -3 -2 -1 -
-0.14 (-6.28 %)
(As of 03/5/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive ADMA News and Ratings via Email

Sign-up to receive the latest news and ratings for ADMA and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

ADMA Biologics (NASDAQ:ADMA) Frequently Asked Questions

Is ADMA Biologics a buy right now?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ADMA Biologics in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" ADMA Biologics stock.
View analyst ratings for ADMA Biologics
or view top-rated stocks.

What stocks does MarketBeat like better than ADMA Biologics?

Wall Street analysts have given ADMA Biologics a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but ADMA Biologics wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is ADMA Biologics' next earnings date?

ADMA Biologics is scheduled to release its next quarterly earnings announcement on Thursday, March 11th 2021.
View our earnings forecast for ADMA Biologics

How were ADMA Biologics' earnings last quarter?

ADMA Biologics, Inc. (NASDAQ:ADMA) announced its quarterly earnings data on Tuesday, November, 10th. The biotechnology company reported ($0.19) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.19). The biotechnology company had revenue of $10.28 million for the quarter, compared to analysts' expectations of $9.55 million. ADMA Biologics had a negative net margin of 166.01% and a negative trailing twelve-month return on equity of 98.83%.
View ADMA Biologics' earnings history

How has ADMA Biologics' stock been impacted by COVID-19 (Coronavirus)?

ADMA Biologics' stock was trading at $2.31 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, ADMA shares have decreased by 9.5% and is now trading at $2.09.
View which stocks have been most impacted by COVID-19

What guidance has ADMA Biologics issued on next quarter's earnings?

ADMA Biologics issued an update on its fourth quarter 2020 Pre-Market earnings guidance on Tuesday, January, 19th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $13.9-13.9 million, compared to the consensus revenue estimate of $12.05 million.

What price target have analysts set for ADMA?

4 brokerages have issued 1-year target prices for ADMA Biologics' shares. Their forecasts range from $6.00 to $11.00. On average, they expect ADMA Biologics' stock price to reach $8.00 in the next year. This suggests a possible upside of 282.8% from the stock's current price.
View analysts' price targets for ADMA Biologics
or view top-rated stocks among Wall Street analysts.

Who are ADMA Biologics' key executives?

ADMA Biologics' management team includes the following people:
  • Mr. Adam S. Grossman, Co-Founder, Pres, CEO & Director (Age 44, Pay $941.16k)
  • Dr. Jerrold B. Grossman Ph.D., D.P.S., Co-Founder & Vice Chairman (Age 73, Pay $70.9k)
  • Mr. Brian Lenz CPA, CPA, Exec. VP & CFO (Age 49, Pay $741.73k)
  • Dr. James Mond, Exec. VP, Chief Scientific Officer & Chief Medical Officer (Age 75, Pay $856.99k)
  • Ms. Kim Tripodo, Exec. Director & Head of Human Resource and Admin. Operations
  • Mr. Skyler Bloom, Director of Investor Relations & Corp. Strategy
  • Ms. Kaitlin Kestenberg, VP of Compliance, Project Management & Clinical Operations
  • Mr. Michael Least, VP of Sales & Commercial Operations
  • Mr. Drew Pantello, VP of Marketing & Corp. Devel.
  • Dr. Gene A. Wetzstein BCOP, Pharm.D., Exec. Director & Head of Scientific Engagement

What is Adam S. Grossman's approval rating as ADMA Biologics' CEO?

9 employees have rated ADMA Biologics CEO Adam S. Grossman on Glassdoor.com. Adam S. Grossman has an approval rating of 29% among ADMA Biologics' employees. This puts Adam S. Grossman in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of ADMA Biologics' key competitors?

What other stocks do shareholders of ADMA Biologics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other ADMA Biologics investors own include Matinas BioPharma (MTNB), Pennsylvania Real Estate Investment Trust (PEI), OrganiGram (OGI), Gran Tierra Energy (GTE), Tilly's (TLYS), Bionano Genomics (BNGO), Novan (NOVN), Cannabics Pharmaceuticals (CNBX), Zosano Pharma (ZSAN) and DHT (DHT).

What is ADMA Biologics' stock symbol?

ADMA Biologics trades on the NASDAQ under the ticker symbol "ADMA."

Who are ADMA Biologics' major shareholders?

ADMA Biologics' stock is owned by a variety of institutional and retail investors. Top institutional investors include BlackRock Inc. (5.74%), Northern Trust Corp (0.90%), Essex Investment Management Co. LLC (0.66%), Magnetar Financial LLC (0.59%), Alyeska Investment Group L.P. (0.49%) and Alyeska Investment Group L.P. (0.49%). Company insiders that own ADMA Biologics stock include Adam S Grossman, Biotest Divestiture Trust, Brian Lenz, James Mond, Jerrold B Grossman, Lawrence P Guiheen, Life Sciences Maste Perceptive and Perceptive Advisors Llc.
View institutional ownership trends for ADMA Biologics

Which major investors are selling ADMA Biologics stock?

ADMA stock was sold by a variety of institutional investors in the last quarter, including Alyeska Investment Group L.P., Alyeska Investment Group L.P., BlackRock Inc., Avantax Advisory Services Inc., Alliancebernstein L.P., Dynamic Technology Lab Private Ltd, Hussman Strategic Advisors Inc., and ProShare Advisors LLC.
View insider buying and selling activity for ADMA Biologics
or view top insider-selling stocks.

Which major investors are buying ADMA Biologics stock?

ADMA stock was purchased by a variety of institutional investors in the last quarter, including Magnetar Financial LLC, Principal Financial Group Inc., Essex Investment Management Co. LLC, Squarepoint Ops LLC, ExodusPoint Capital Management LP, GSA Capital Partners LLP, New York Life Investments Alternatives, and Meridian Wealth Management LLC. Company insiders that have bought ADMA Biologics stock in the last two years include Adam S Grossman, Brian Lenz, James Mond, Jerrold B Grossman, Lawrence P Guiheen, Life Sciences Maste Perceptive, and Perceptive Advisors Llc.
View insider buying and selling activity for ADMA Biologics
or or view top insider-buying stocks.

How do I buy shares of ADMA Biologics?

Shares of ADMA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is ADMA Biologics' stock price today?

One share of ADMA stock can currently be purchased for approximately $2.09.

How much money does ADMA Biologics make?

ADMA Biologics has a market capitalization of $197.61 million and generates $29.35 million in revenue each year. The biotechnology company earns $-48,280,000.00 in net income (profit) each year or ($0.92) on an earnings per share basis.

How many employees does ADMA Biologics have?

ADMA Biologics employs 313 workers across the globe.

What is ADMA Biologics' official website?

The official website for ADMA Biologics is www.admabiologics.com.

Where are ADMA Biologics' headquarters?

ADMA Biologics is headquartered at 465 STATE ROUTE 17, RAMSEY NJ, 07446.

How can I contact ADMA Biologics?

ADMA Biologics' mailing address is 465 STATE ROUTE 17, RAMSEY NJ, 07446. The biotechnology company can be reached via phone at 201-478-5552 or via email at [email protected]

This page was last updated on 3/6/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.